Homepage
Author:
Apogee Therapeutics
Posted Date:
March 24, 2026
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics
March 24, 2026
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics
March 23, 2026
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics
March 23, 2026
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
Apogee Therapeutics
March 22, 2026
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
Apogee Therapeutics
March 2, 2026
Apogee Therapeutics to Participate in Upcoming March Conferences
Apogee Therapeutics
February 24, 2026
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Apogee Therapeutics
February 7, 2026
